These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 39039143)
1. Identifying strategies to improve adverse drug reporting through key informant interviews among community pharmacists in a developing country. Nduka SO; Ibe CO; Nwaodu MA; Robert CC Sci Rep; 2024 Jul; 14(1):16821. PubMed ID: 39039143 [TBL] [Abstract][Full Text] [Related]
2. Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Li R; Curtain C; Bereznicki L; Zaidi STR Int J Clin Pharm; 2018 Aug; 40(4):878-889. PubMed ID: 30097819 [TBL] [Abstract][Full Text] [Related]
3. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. Adisa R; Omitogun TI BMC Health Serv Res; 2019 Dec; 19(1):926. PubMed ID: 31796034 [TBL] [Abstract][Full Text] [Related]
4. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. Hajj A; Hallit S; Ramia E; Salameh P; Curr Med Res Opin; 2018 Jan; 34(1):149-156. PubMed ID: 28758813 [TBL] [Abstract][Full Text] [Related]
5. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Irujo M; Beitia G; Bes-Rastrollo M; Figueiras A; Hernández-Díaz S; Lasheras B Drug Saf; 2007; 30(11):1073-82. PubMed ID: 17973543 [TBL] [Abstract][Full Text] [Related]
6. Awareness, knowledge, attitude, and practice of adverse drug reaction reporting among health workers in primary health centres participating in seasonal malaria chemoprevention campaign in Nigeria in 2022: a cross-sectional survey. Rotimi K; Fagbemi B; Omole G; Biambo AA; Ibinaiye T; Iwegbu A; Ogunmola O; Oguoma C; Oresanya O BMC Health Serv Res; 2024 Aug; 24(1):952. PubMed ID: 39164692 [TBL] [Abstract][Full Text] [Related]
7. Barriers and Facilitators Influencing Real-time and Digital-Based Reporting of Adverse Drug Reactions by Community Pharmacists: Qualitative Study Using the Task-Technology Fit Framework. Fossouo Tagne J; Yakob RA; Mcdonald R; Wickramasinghe N Interact J Med Res; 2022 Oct; 11(2):e40597. PubMed ID: 36222800 [TBL] [Abstract][Full Text] [Related]
8. Motivation and Knowledge of Portuguese Community Pharmacists Towards the Reporting of Suspected Adverse Reactions to Medicines: A Cross-Sectional Survey. Ferreira-da-Silva R; Alves JM; Vieira C; Silva AM; Marques J; Morato M; Polónia JJ; Ribeiro-Vaz I J Community Health; 2023 Apr; 48(2):295-308. PubMed ID: 36401737 [TBL] [Abstract][Full Text] [Related]
9. Exploring the knowledge, perception, and practice of community pharmacists in Saudi Arabia toward pharmacovigilance and adverse drug reaction reporting. A nationwide survey. Khardali A Sci Rep; 2024 Feb; 14(1):4819. PubMed ID: 38413787 [TBL] [Abstract][Full Text] [Related]
10. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation. Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598 [TBL] [Abstract][Full Text] [Related]
11. Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Aldryhim AY; Alomair A; Alqhtani M; Mahmoud MA; Alshammari TM; Pont LG; Kamal KM; Aljadhey H; Mekonnen AB; Alwhaibi M; Balkhi B; Alhawassi TM Expert Opin Drug Saf; 2019 Aug; 18(8):745-752. PubMed ID: 31232612 [No Abstract] [Full Text] [Related]
12. Community Pharmacists' Views and Experiences with ADR Reporting for Complementary Medicines: A Qualitative Study in New Zealand. Barnes J; Butler R Drug Saf; 2020 Nov; 43(11):1157-1170. PubMed ID: 32975740 [TBL] [Abstract][Full Text] [Related]
13. ADVERSE DRUG REPORTING IN COMMUNITY PHARMACY PRACTICE IN THE POMERANIAN DISTRICT IN POLAND. Zimmermann A; Gaworska-Krzeminska A; Flis A Acta Pol Pharm; 2016 Sep; 73(5):1389-1396. PubMed ID: 29638080 [TBL] [Abstract][Full Text] [Related]
14. Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study. Shareef J; Sridhar SB; Bhupathyraaj M; Shariff A; Thomas S Ther Adv Drug Saf; 2024; 15():20420986241285930. PubMed ID: 39381061 [TBL] [Abstract][Full Text] [Related]
15. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Toklu HZ; Uysal MK Pharm World Sci; 2008 Oct; 30(5):556-62. PubMed ID: 18350373 [TBL] [Abstract][Full Text] [Related]
16. A qualitative exploration of knowledge, attitudes and practices of hospital pharmacists towards adverse drug reaction reporting system in Lahore, Pakistan. Hussain R; Hassali MA; Hashmi F; Farooqui M J Pharm Policy Pract; 2018; 11():16. PubMed ID: 30034811 [TBL] [Abstract][Full Text] [Related]
17. Predictive Factors of Spontaneous Reporting of Adverse Drug Reactions among Community Pharmacists. Yu YM; Lee E; Koo BS; Jeong KH; Choi KH; Kang LK; Lee MS; Choi KH; Oh JM; Shin WG PLoS One; 2016; 11(5):e0155517. PubMed ID: 27192159 [TBL] [Abstract][Full Text] [Related]
18. Linking Activity Theory Within User-Centered Design: Novel Framework to Inform Design and Evaluation of Adverse Drug Reaction Reporting Systems in Pharmacy. Fossouo Tagne J; Yakob RA; Mcdonald R; Wickramasinghe N JMIR Hum Factors; 2023 Feb; 10():e43529. PubMed ID: 36826985 [TBL] [Abstract][Full Text] [Related]
19. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498 [TBL] [Abstract][Full Text] [Related]
20. Stakeholders' knowledge, attitudes and practices to pharmacovigilance and adverse drug reaction reporting in clinical trials: a mixed methods study. Riordan DO; Kinane M; Walsh KA; Shiely F; Eustace J; Bermingham M Eur J Clin Pharmacol; 2020 Oct; 76(10):1363-1372. PubMed ID: 32507924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]